APEX-AV trial evaluated the safety and efficacy of the AlphaVac F1885 System for treating acute intermediate-risk pulmonary embolism (PE). The study found significant reductions in the right ventricular/left ventricular diameter ratio and pulmonary arterial pressure within 48 hours post-procedure, along with a 35.5% mean reduction in clot burden. The treatment demonstrated a low rate of major adverse events, primarily minor access site bleeding. Drs. Sahil Parikh, Mona Ranade, William Brent Keeling, and Kenneth Rosenfield discuss the trial highlights in this video interview. Read the article: https://doi.org/10.1016/j.jscai.2024.102463